Your session is about to expire
What is Xalkori
CrizotinibThe Generic name of this drug
Treatment SummaryCrizotinib is a medication used to treat non-small cell lung cancer (NSCLC). It works by blocking the receptor tyrosine kinase and is only used when testing with Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit confirms the presence of an ALK fusion gene. The FDA approved Crizotinib in 2011.
Xalkoriis the brand name
Xalkori Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Xalkori
Crizotinib
2011
2
Approved as Treatment by the FDA
Crizotinib, also known as Xalkori, is approved by the FDA for 1 uses which include Malignant Neoplasms .Malignant Neoplasms
Effectiveness
How Xalkori Affects PatientsIn a study with 37 people with types of cancer that did not respond to other treatments, two with non-small cell lung cancer (NSCLC) responded to crizotinib. Those with advanced ALK-positive disease who took crizotinib had a 72% chance of surviving 6 months without the cancer progressing, and a 54% chance of surviving two years. Taking crizotinib may lead to liver damage, lung inflammation, heart problems, vision problems, pregnancy risks, and gastrointestinal issues in pediatric or young adult patients with ALCL or IMT.
How Xalkori works in the bodyCrizotinib is a medicine that stops cancer cells from growing. It works by targeting proteins called ALK, c-MET, ROS1, and Recepteur d'Origine Nantais (RON) which help keep cancer cells alive. In laboratory tests, crizotinib was shown to stop the phosphorylation of these proteins in cancer cells, which stops them from growing. In mice with tumors that expressed ALK or c-MET, crizotinib had an antitumor effect.
When to interrupt dosage
The proposed dose of Xalkori is contingent upon the diagnosed circumstance. The measure of dosage is contingent upon the method of administration (e.g. Oral or Capsule) featured in the table beneath.Condition
Dosage
Administration
Malignant Neoplasms
, 200.0 mg, 250.0 mg
, Oral, Capsule, Capsule - Oral
Ki-1+ Anaplastic Large Cell Lymphoma
, 200.0 mg, 250.0 mg
, Oral, Capsule, Capsule - Oral
Warnings
There are 20 known major drug interactions with Xalkori.Common Xalkori Drug Interactions
Drug Name
Risk Level
Description
Anagrelide
Major
The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Anagrelide.
Asenapine
Major
The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Asenapine.
Bendamustine
Major
The serum concentration of Bendamustine can be increased when it is combined with Crizotinib.
Binimetinib
Major
The serum concentration of Binimetinib can be increased when it is combined with Crizotinib.
Carfilzomib
Major
The serum concentration of Carfilzomib can be increased when it is combined with Crizotinib.
Xalkori Toxicity & Overdose RiskThe recommended dose of crizotinib is 250 mg twice daily. In the event of an overdose, supportive measures and symptomatic treatments should be used. There is no antidote for crizotinib, and tests have shown that it can be damaging to cells and has not been tested for its ability to cause cancer. In animal tests, large doses of crizotinib caused single-cell necrosis in female rats and testicular degeneration in male rats.
Xalkori Novel Uses: Which Conditions Have a Clinical Trial Featuring Xalkori?
Presently, there are 9 active trials investigating the potential of Xalkori in providing therapeutic benefits for Malignant Neoplasms.Condition
Clinical Trials
Trial Phases
Malignant Neoplasms
12 Actively Recruiting
Phase 3, Phase 1, Phase 2
Ki-1+ Anaplastic Large Cell Lymphoma
7 Actively Recruiting
Not Applicable, Phase 2, Phase 1
Xalkori Reviews: What are patients saying about Xalkori?
5Patient Review
10/9/2018 This treatment has been a life-saver for me. In the two years since I've been taking it, my CEA levels have dropped from 40 to 5.8. It's given me hope and I can't thank the team who invented it enough.
5Patient Review
1/28/2015 I've been on this medication for a while now, and it's helped me immensely. I did have some trouble with diarrhea when I first started taking it, but that has since gone away. I do have a slow heart rate, but it's manageable. Additionally, my vision has actually improved since starting this medication, which is an unexpected bonus.
5Patient Review
11/12/2013 I've been taking this medication for over a year now with few negative side effects. The only downside is that I sometimes feel nauseous when I take it on an empty stomach, but otherwise it's helped me immensely.
5Patient Review
6/29/2012 I've been on this medication for six months and have seen significant improvement in both my lungs. I no longer experience shortness of breath or lack energy. This has been the most effective chemotherapy I've had in more than seven years by far, and with little to no negative side effects!
5Patient Review
5/21/2014 I've been on this drug for ten months with no terrible side effects. My cancer is all but gone, and my lymph nodes have shrunk back to a healthy size.
4.7Patient Review
5/17/2015 I've been using Xalkori for 39 months to treat my stage IV lung cancer. I experienced some side effects when I first started, like vision problems and nausea/constipation, but those have since become manageable. The only issue I'm having now is with lymphedema in my legs, but that's a small price to pay for such an effective cancer treatment.
2.7Patient Review
4/4/2012 I have experienced some side effects, like nausea and vomiting, as well as visual disturbances. However, I am pleased that the cancer has not spread elsewhere and that the size of a lymph node on my bronchus has decreased.
2Patient Review
4/25/2014 I believe this treatment is actually killing my mother faster than the cancer would have. The swelling has made her unable to walk and now her body is shutting down from lack of circulation.
Patient Q&A Section about xalkori
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Is Xalkori chemotherapy?
"A targeted therapy is a cancer treatment that targets the changes in cancer cells that help them grow, divide, and spread.
Crizotinib is the name for the chemotherapy drug that is trade-named Xalkori. In some cases, health care professionals may use Xalkori when referring to the generic drug crizotinib. Crizotinib is a targeted therapy, which is a cancer treatment that targets the changes in cancer cells that help them grow, divide, and spread."
Answered by AI
What kind of drug is Xalkori?
"Xalkori is taken as a pill and can be used to treat non-small cell lung cancer. It can be used alone or with other medications, and belongs to a class of drugs called antineoplastics, which are drugs that kill cancer cells."
Answered by AI
How effective is Xalkori?
"74% of patients responded positively to Xalkori treatment, as opposed to the 45% who responded positively to chemotherapy infusions. On average, those who underwent Xalkori treatment saw their tumors shrink for 11.3 months, while those who received chemotherapy only saw their tumors shrink for 5.3 months."
Answered by AI
What does Xalkori treat?
"Crizotinib is a targeted cancer drug that treats advanced non small cell lung cancer (NSCLC) that has changes in either the ALK or ROS1 gene."
Answered by AI